CN112481156B - 一株能够缓解腹泻的鼠李糖乳杆菌lr519及其组合物 - Google Patents
一株能够缓解腹泻的鼠李糖乳杆菌lr519及其组合物 Download PDFInfo
- Publication number
- CN112481156B CN112481156B CN202011343440.9A CN202011343440A CN112481156B CN 112481156 B CN112481156 B CN 112481156B CN 202011343440 A CN202011343440 A CN 202011343440A CN 112481156 B CN112481156 B CN 112481156B
- Authority
- CN
- China
- Prior art keywords
- effect
- diarrhea
- lactobacillus rhamnosus
- parts
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 206010012735 Diarrhoea Diseases 0.000 title claims abstract description 41
- 241000218588 Lactobacillus rhamnosus Species 0.000 title claims abstract description 34
- 239000000843 powder Substances 0.000 claims abstract description 51
- 230000001580 bacterial effect Effects 0.000 claims abstract description 34
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 22
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 22
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 22
- 241000894006 Bacteria Species 0.000 claims description 19
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 12
- 235000004936 Bromus mango Nutrition 0.000 claims description 8
- 235000014826 Mangifera indica Nutrition 0.000 claims description 8
- 235000009184 Spondias indica Nutrition 0.000 claims description 8
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 8
- 235000013399 edible fruits Nutrition 0.000 claims description 8
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 6
- 229930003268 Vitamin C Natural products 0.000 claims description 6
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 6
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 6
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 6
- 229960003451 lactitol Drugs 0.000 claims description 6
- 235000010448 lactitol Nutrition 0.000 claims description 6
- 239000000832 lactitol Substances 0.000 claims description 6
- 235000019154 vitamin C Nutrition 0.000 claims description 6
- 239000011718 vitamin C Substances 0.000 claims description 6
- 238000004321 preservation Methods 0.000 claims description 5
- 240000007228 Mangifera indica Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 49
- 239000006041 probiotic Substances 0.000 abstract description 48
- 235000018291 probiotics Nutrition 0.000 abstract description 48
- 230000000529 probiotic effect Effects 0.000 description 39
- 230000000052 comparative effect Effects 0.000 description 33
- 230000002401 inhibitory effect Effects 0.000 description 32
- 241000588724 Escherichia coli Species 0.000 description 23
- 230000035622 drinking Effects 0.000 description 11
- 241001093152 Mangifera Species 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 241000607142 Salmonella Species 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 206010012742 Diarrhoea infectious Diseases 0.000 description 4
- 230000003385 bacteriostatic effect Effects 0.000 description 4
- 230000002416 diarrheagenic effect Effects 0.000 description 4
- 230000000741 diarrhetic effect Effects 0.000 description 4
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 3
- 108010079723 Shiga Toxin Proteins 0.000 description 3
- 241000607768 Shigella Species 0.000 description 3
- 241000607766 Shigella boydii Species 0.000 description 3
- 241000607764 Shigella dysenteriae Species 0.000 description 3
- 241000607762 Shigella flexneri Species 0.000 description 3
- 241000607760 Shigella sonnei Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 230000000369 enteropathogenic effect Effects 0.000 description 3
- 230000000688 enterotoxigenic effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 229940007046 shigella dysenteriae Drugs 0.000 description 3
- 229940115939 shigella sonnei Drugs 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241000607528 Aeromonas hydrophila Species 0.000 description 1
- 206010004016 Bacterial diarrhoea Diseases 0.000 description 1
- 241000605059 Bacteroidetes Species 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000223935 Cryptosporidium Species 0.000 description 1
- 241000605716 Desulfovibrio Species 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 206010072104 Fructose intolerance Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 241000224467 Giardia intestinalis Species 0.000 description 1
- 206010019878 Hereditary fructose intolerance Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000577946 Sarcodon Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 244000309743 astrovirus Species 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 229940007078 entamoeba histolytica Drugs 0.000 description 1
- 229940085435 giardia lamblia Drugs 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明属于益生菌技术领域，提出了一株能够缓解腹泻的鼠李糖乳杆菌LR519及其组合物，所述组合物包括质量比为(2‑3)：1的鼠李糖乳杆菌LR519菌粉与植物乳杆菌LP45菌粉。通过上述技术方案，解决了现有技术中益生菌仍存在缓解腹泻见效慢，效果差的问题。
Description
技术领域
本发明属于益生菌技术领域，涉及一株能够缓解腹泻的鼠李糖乳杆菌LR519及其组合物。
背景技术
腹泻，指每天排出三次或三次以上的稀便或液体样便的一种临床状态。感染细菌、病毒或寄生虫等病原体是发生腹泻的最主要原因，这部分腹泻又被称为感染性腹泻或胃肠炎，通过食用被病原体污染的食物或水，以及人与人直接接触感染。感染性腹泻的发生与传播被认为是卫生条件较差的结果。通常在接触病原体12-72小时后发生腹泻症状，导致感染性腹泻的病原体主要被认为病毒、细菌与寄生虫。对人致泻的病毒主要有：轮状病毒、诺如病毒、腺病毒、星状病毒等；细菌主要包括：致泻性大肠埃希菌、霍乱弧菌、副溶血弧菌、弯曲菌、耶尔森菌、志贺菌、沙口菌、嗜水气单胞菌；寄生虫主要为溶组织内阿米巴、兰氏贾第鞭毛虫、隐孢子虫等造成腹泻的其他原因还包括：甲状腺机能亢进、果糖不耐症、炎性肠病、药物影响及应激性结肠综合征等。
2010-2014年在我国17省进行感染性腹泻病原学监测，对20767例进行了全部细菌性病原谱分析发现，致泻性大肠埃希菌是细菌性腹泻病原谱的最主要病原体，占全部腹泻病例的40.31％，其次为沙门氏菌(24.68％)、志贺菌(20.59％)。
而长期过量饮酒也会导致腹泻的发生，使小肠需氧菌过生长，乳酸杆菌减少可增强小肠细菌的致病性。酗酒者和健康人相比，肠道菌群结构有显著差异，其中酗酒人群肠道中拟杆菌门和放线菌门明显降低。且饮酒会导致肠道中大肠杆菌、沙门氏菌、空肠弯曲菌、志贺氏菌大量增多，引发机体腹泻。益生菌是现有技术中治疗腹泻的有效手段，但是现有的益生菌仍存在见效慢，效果差的不足。
发明内容
本发明提出一株能够缓解腹泻的鼠李糖乳杆菌LR519及其组合物，解决了现有技术中益生菌仍存在缓解腹泻见效慢，效果差的问题。
本发明的技术方案是这样实现的：一种能够缓解腹泻的鼠李糖乳杆菌LR519组合物，所述组合物包括质量比为(2-3)：1的鼠李糖乳杆菌LR519菌粉与植物乳杆菌LP45菌粉。
进一步地，所述组合物包括质量比为2：1的鼠李糖乳杆菌LR519菌粉与植物乳杆菌LP45菌粉。
上述能够缓解腹泻的鼠李糖乳杆菌LR519组合物的应用，用于制备缓解腹泻的食品。
进一步地，按质量份数计，所述食品包括7-11份混合菌粉A，33-37份乳糖醇，27-31份低聚果糖，17-21份水苏糖，0.1-0.3份维生素C，5-9份芒果水果粉；
所述混合菌粉A包括质量比为(2-3)：1的鼠李糖乳杆菌LR519菌粉与植物乳杆菌LP45菌粉。
进一步地，按质量份数计，所述食品包括7-11份混合菌粉A，33-37份乳糖醇，27-31份低聚果糖，17-21份水苏糖，0.1-0.3份维生素C，5-9份芒果水果粉；
所述混合菌粉A包括质量比为2：1的鼠李糖乳杆菌LR519菌粉与植物乳杆菌LP45菌粉。
本发明的工作原理及有益效果为：
1、本发明中通过对鼠李糖乳杆菌LR519菌粉与植物乳杆菌LP45菌粉的复配，提高了单一菌种对于有害菌(致泻性大肠杆菌、沙门氏菌和金黄色葡萄球菌)的抑制效果，在服用本发明组合物前有酒后当日腹泻症状21人，有次日腹泻症状26人，在服用本发明组合物后当日腹泻1人，其余正常(有效率95.2％)，次日腹泻10人，16人腹泻症状消失(有效率61.5％)，对于酒后当日腹泻和次日腹泻均有显著缓解效果，解决了现有技术中益生菌缓解腹泻见效慢，效果差的问题。
2、本发明中通过水苏糖和芒果水果粉的复配添加，进一步提高了鼠李糖乳杆菌LR519菌粉与植物乳杆菌LP45菌粉缓解便秘的作用。
附图说明
下面结合附图和具体实施方式对本发明作进一步详细的说明。
图1为本发明实施例1益生菌组合物抑制肠道集聚性大肠埃希氏菌EAEC的效果图。
图2为本发明实施例1益生菌组合物抑制产肠毒素大肠埃希氏ETEC的效果图。
图3为本发明实施例1益生菌组合物抑制产志贺毒素大肠埃希氏菌STEC的效果图。
图4为本发明实施例1益生菌组合物抑制肠道致病性大肠埃希氏菌EPEC的效果图。
图5为本发明实施例1益生菌组合物抑制肠道出血性大肠埃希氏菌EHEC的效果图。
图6为本发明实施例1益生菌组合物抑制肠道侵袭性大肠埃希氏菌EIEC的效果图。
图7为本发明实施例1益生菌组合物抑制鲍氏志贺菌的效果图。
图8为本发明实施例1益生菌组合物抑制福氏志贺菌的效果图。
图9为本发明实施例1益生菌组合物抑制宋内志贺菌的效果图。
图10为本发明实施例1益生菌组合物抑制痢疾志贺菌的效果图。
图11为本发明实施例1益生菌组合物抑制肠炎沙门氏菌的效果图。
图12为本发明实施例1益生菌组合物抑制金黄色葡萄球菌的效果图。
图13为本发明比较例1益生菌组合物抑制肠道集聚性大肠埃希氏菌EAEC的效果图。
图14为本发明比较例1益生菌组合物抑制产肠毒素大肠埃希氏ETEC的效果图。
图15为本发明比较例1益生菌组合物抑制产志贺毒素大肠埃希氏菌STEC的效果图。
图16为本发明比较例1益生菌组合物抑制肠道致病性大肠埃希氏菌EPEC的效果图。
图17为本发明比较例1益生菌组合物抑制肠道出血性大肠埃希氏菌EHEC的效果图。
图18为本发明比较例1益生菌组合物抑制肠道侵袭性大肠埃希氏菌EIEC的效果图。
图19为本发明比较例1益生菌组合物抑制鲍氏志贺菌的效果图。
图20为本发明比较例1益生菌组合物抑制福氏志贺菌的效果图。
图21为本发明比较例1益生菌组合物抑制宋内志贺菌的效果图。
图22为本发明比较例1益生菌组合物抑制痢疾志贺菌的效果图。
图23为本发明比较例1益生菌组合物抑制肠炎沙门氏菌的效果图。
图24为本发明比较例1益生菌组合物抑制金黄色葡萄球菌的效果图。
图25为本发明比较例2益生菌组合物抑制肠道集聚性大肠埃希氏菌EAEC的效果图。
图26为本发明比较例2益生菌组合物抑制产肠毒素大肠埃希氏ETEC的效果图。
图27为本发明比较例2益生菌组合物抑制产志贺毒素大肠埃希氏菌STEC的效果图。
图28为本发明比较例2益生菌组合物抑制肠道致病性大肠埃希氏菌EPEC的效果图。
图29为本发明比较例2益生菌组合物抑制肠道出血性大肠埃希氏菌EHEC的效果图。
图30为本发明比较例2益生菌组合物抑制肠道侵袭性大肠埃希氏菌EIEC的效果图。
图31为本发明比较例2益生菌组合物抑制鲍氏志贺菌的效果图。
图32为本发明比较例2益生菌组合物抑制福氏志贺菌的效果图。
图33为本发明比较例2益生菌组合物抑制宋内志贺菌的效果图。
图34为本发明比较例2益生菌组合物抑制痢疾志贺菌的效果图。
图35为本发明比较例2益生菌组合物抑制肠炎沙门氏菌的效果图。
图36为本发明比较例2益生菌组合物抑制金黄色葡萄球菌的效果图。
具体实施方式
下面将结合本发明实施例，对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。本发明涉及到的益生菌均由河北一然生物科技有限公司提供，其中鼠李糖乳杆菌LR519与植物乳杆菌LP45均已在专利公报中公开，公开的专利申请文件申请号为201911301091.1，申请日2019.12.17，发明名称为缓解腹泻及痔疮的益生菌组合物，并且已经经过国家知识产权局承认的用于专利程序的保藏机构保藏，植物乳杆菌(Lactobacillus planta rum)LP45，保藏编号为CGMCCNo.8072；鼠李糖乳杆菌(Lactobacillus rhamnosus)LR519，保藏编号为CGMCC No.15969；可以认定为公众可以得到、而不要求进行保藏的情形。
一、实施例
实施例1
一种能够缓解腹泻的鼠李糖乳杆菌LR519组合物，所述组合物包括质量比为2：1的鼠李糖乳杆菌LR519菌粉与植物乳杆菌LP45菌粉。
实施例2
一种能够缓解腹泻的鼠李糖乳杆菌LR519组合物，所述组合物包括质量比为2.5：1的鼠李糖乳杆菌LR519菌粉与植物乳杆菌LP45菌粉。
实施例3
一种能够缓解腹泻的鼠李糖乳杆菌LR519组合物，所述组合物包括质量比为3：1的鼠李糖乳杆菌LR519菌粉与植物乳杆菌LP45菌粉。
比较例1
与实施例1相比，区别仅在于，未包括鼠李糖乳杆菌LR519菌粉。
比较例2
与实施例1相比，区别仅在于，未包括植物乳杆菌LP45菌粉。
致泻性大肠杆菌、沙门氏菌和金黄色葡萄球菌与腹泻状态的发生高度相关，因此以实施例1及比较例1～2的益生菌为目标菌，进行如下目标菌体外抑菌实验：
有害菌(致泻性大肠杆菌、沙门氏菌和金黄色葡萄球菌)活化三代后，用1×108CFU/mL浓度的脱硫弧菌涂布到新鲜的哥伦比亚血平板上，立即放入牛津杯，加入各待测目标菌100μL，微需氧条件下固定1h。培养72h后，测量抑菌环直径，结果如下表1，效果图见图1-6。
表1
从上表中数据可以看出，目标菌体外抑菌实验加入的目标菌总量是相同的，实施例1采用鼠李糖乳杆菌LR519和植物乳杆菌LP45协同，比较例1-2单独采用鼠李糖乳杆菌LR519或植物乳杆菌LP45，相较于实施例1，比较例1-2抑菌圈的直径减小，可见本发明采用鼠李糖乳杆菌LR519和植物乳杆菌LP45复配协同提高了抑菌效果。
二、应用实施例
应用实施例1
按质量份数计，所述食品包括10份混合菌粉A，35份乳糖醇，30份低聚果糖，20份水苏糖，0.2份维生素C，8份芒果水果粉；
所述混合菌粉A包括质量比为2：1的鼠李糖乳杆菌LR519菌粉与植物乳杆菌LP45菌粉。
应用实施例2
按质量份数计，所述食品包括7份混合菌粉A，37份乳糖醇，27份低聚果糖，21份水苏糖，0.1份维生素C，9份芒果水果粉；
所述混合菌粉A包括质量比为2.5：1的鼠李糖乳杆菌LR519菌粉与植物乳杆菌LP45菌粉。
应用实施例3
按质量份数计，所述食品包括11份混合菌粉A，33份乳糖醇，31份低聚果糖，17份水苏糖，0.3份维生素C，5份芒果水果粉；
所述混合菌粉A包括质量比为3：1的鼠李糖乳杆菌LR519菌粉与植物乳杆菌LP45菌粉。
对比应用实施例1
与应用实施例1相比，区别仅在于不包括水苏糖。
对比应用实施例2
与应用实施例1相比，区别仅在于不包括芒果水果粉。
腹泻人群试服
1、试服方法
本实验招募有酒后腹泻人群46人饮酒前后服用应用实施例1的产品，46人饮酒前后服用对比应用实施例1的产品，46人饮酒前后服用对比应用实施例2的产品，记录饮酒当日及次日排便情况。
对招募人群统计分析发现，在服用应用实施例1前有酒后当日腹泻症状21人，有次日腹泻症状26人，在服用应用实施例1后当日腹泻1人，其余正常(有效率95.2％)，次日腹泻10人，16人腹泻症状消失(有效率61.5％)。以上结果表明本发明益生菌组合物对于酒后当日腹泻和次日腹泻均有显著缓解效果。
表2服用前后肠道不适的缓解情况
以上仅为本发明的较佳实施例而已，并不用以限制本发明，凡在本发明的精神和原则之内，所作的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内。
Claims (2)
1.一种能够缓解腹泻的鼠李糖乳杆菌LR519组合物，其特征在于，所述组合物由以下质量份组分组成：7-11份混合菌粉A，33-37份乳糖醇，27-31份低聚果糖，17-21份水苏糖，0.1-0.3份维生素C，5-9份芒果水果粉；
混合菌粉A为质量比为（2-3）：1的鼠李糖乳杆菌LR519菌粉与植物乳杆菌LP45菌粉；
鼠李糖乳杆菌LR519的保藏编号为CGMCC No.15969；植物乳杆菌LP45的保藏编号为CGMCCNo.8072。
2.根据权利要求1所述的一种能够缓解腹泻的鼠李糖乳杆菌LR519组合物，其特征在于，所述鼠李糖乳杆菌LR519菌粉与植物乳杆菌LP45的质量比为2：1。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011343440.9A CN112481156B (zh) | 2020-11-26 | 2020-11-26 | 一株能够缓解腹泻的鼠李糖乳杆菌lr519及其组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011343440.9A CN112481156B (zh) | 2020-11-26 | 2020-11-26 | 一株能够缓解腹泻的鼠李糖乳杆菌lr519及其组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112481156A CN112481156A (zh) | 2021-03-12 |
| CN112481156B true CN112481156B (zh) | 2022-07-22 |
Family
ID=74934779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011343440.9A Active CN112481156B (zh) | 2020-11-26 | 2020-11-26 | 一株能够缓解腹泻的鼠李糖乳杆菌lr519及其组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112481156B (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101810631A (zh) * | 2010-02-26 | 2010-08-25 | 中国食品发酵工业研究院 | 水苏糖在制备防治腹泻药物中的应用 |
| CN108850397A (zh) * | 2018-06-15 | 2018-11-23 | 广东燕岭生命科技股份有限公司 | 一种止腹泻的益生菌凝胶糖果及其制备方法 |
| CN110016442A (zh) * | 2019-02-21 | 2019-07-16 | 河北一然生物科技有限公司 | 鼠李糖乳杆菌及其复合菌粉在防治阴道炎制品中的应用 |
| CN113729228A (zh) * | 2020-05-29 | 2021-12-03 | 安琪纽特股份有限公司 | 用于预防或改善腹泻的组合物及其制备方法和应用 |
-
2020
- 2020-11-26 CN CN202011343440.9A patent/CN112481156B/zh active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101810631A (zh) * | 2010-02-26 | 2010-08-25 | 中国食品发酵工业研究院 | 水苏糖在制备防治腹泻药物中的应用 |
| CN108850397A (zh) * | 2018-06-15 | 2018-11-23 | 广东燕岭生命科技股份有限公司 | 一种止腹泻的益生菌凝胶糖果及其制备方法 |
| CN110016442A (zh) * | 2019-02-21 | 2019-07-16 | 河北一然生物科技有限公司 | 鼠李糖乳杆菌及其复合菌粉在防治阴道炎制品中的应用 |
| CN113729228A (zh) * | 2020-05-29 | 2021-12-03 | 安琪纽特股份有限公司 | 用于预防或改善腹泻的组合物及其制备方法和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112481156A (zh) | 2021-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Synergic interactions between polyphenols and gut microbiota in mitigating inflammatory bowel diseases | |
| EP2712318B1 (en) | Composition comprising probiotic bacteria capable of restoring the barrier effect of the stomach which is lost during pharmalogical treatment of gastric hyperacidity | |
| JP6130379B2 (ja) | 胃酸過多の薬物処置中に失われる胃自体の障壁効果を修復することができるプロバイオティック細菌と組み合わされたｎ−アセチルシステインおよび／またはマイクロカプセル化胃保護型リゾチームを含む組成物 | |
| CA3026414A1 (en) | Compositions and methods for treating inflammatory bowel diseases (ibds) and other disorders | |
| WO2009024429A2 (en) | Gut flora and weight management | |
| Del Piano et al. | Correlation between chronic treatment with proton pump inhibitors and bacterial overgrowth in the stomach: any possible beneficial role for selected lactobacilli? | |
| BRPI1011277B1 (pt) | Produto de bacteriocina lactobacillus pentosus, alimento e composições farmacêuticas contendo o mesmo e uso do mesmo | |
| JP2010285425A (ja) | 腸内細菌叢構成比率調整剤 | |
| Tabashsum et al. | Effect of conjugated linoleic acid overproducing Lactobacillus with berry pomace phenolic extracts on Campylobacter jejuni pathogenesis | |
| Kim et al. | A study on the prevention of salmonella infection by using the aggregation characteristics of lactic Acid bacteria | |
| Reid | Probiotics to prevent the need for, and augment the use of, antibiotics | |
| Adamu et al. | A review on Escherichia coli O157: H7-the super pathogen | |
| Chon et al. | The effects of a vegetable‐derived probiotic lactic acid bacterium on the immune response | |
| CN112481156B (zh) | 一株能够缓解腹泻的鼠李糖乳杆菌lr519及其组合物 | |
| Hu et al. | L. johnsonii, L. plantarum, and L. rhamnosus alleviated Enterohaemorrhagic Escherichia coli-induced diarrhoea in mice by regulating gut microbiota | |
| Galindo | Lactobacillus plantarum 44A as a live feed supplement for freshwater fish | |
| Koley et al. | Assessment of antimicrobial activity of different phytochemicals against enteric diseases in different animal models | |
| Kang et al. | In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus plantarum pH3A, monolaurin, and grapefruit seed extract | |
| Aditya et al. | Antagonistic effects of phenolic extracts of Chokeberry pomace on E. coli O157: H7 but not on probiotic and normal bacterial flora | |
| Namba et al. | Inhibitory Effects ofBifidobacterium longumon EnterohemorrhagicEscherichia coliO157: H7 | |
| Goker et al. | Preliminary study on stimulatory and inhibitory effects of aldehydes from the green leaf volatiles family on beneficial and pathogenic bacteria from the intestine. | |
| Yakoob et al. | Anti-Helicobacter pylori activity and inhibition of Helicobacter pylori-induced release of IL-8 in AGS cells by plant extracts | |
| MuhammedTukur et al. | A Review on Public Health Concern Caused by Escherichia coli O157: H7 | |
| Lolekha | Consequences of treatment of gastrointestinal infections | |
| Catalao Dionisio et al. | In vitro antimicrobial activity of Douro wines against clinical Helicobacter pylori strains |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 050800 No. 16, bangxiu East Road, North District, high tech Industrial Development Zone, Zhengding County, Zhengding District, China (Hebei) pilot Free Trade Zone, Shijiazhuang City, Hebei Province Applicant after: Hebei Yiran Biotechnology Co.,Ltd. Address before: 050899 No.16, bangxiu East Road, Zhengding high tech Development Zone, Shijiazhuang City, Hebei Province Applicant before: HEBEI INATURAL BIOTECHNOLOGY Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |